|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HSPB11 |
Gene summary for HSPB11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HSPB11 | Gene ID | 51668 |
| Gene name | heat shock protein family B (small) member 11 | |
| Gene Alias | C1orf41 | |
| Cytomap | 1p32.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9Y547 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51668 | HSPB11 | GSM4909281 | Human | Breast | IDC | 1.73e-12 | 4.73e-01 | 0.21 |
| 51668 | HSPB11 | GSM4909282 | Human | Breast | IDC | 7.42e-48 | 8.77e-01 | -0.0288 |
| 51668 | HSPB11 | GSM4909285 | Human | Breast | IDC | 9.58e-21 | 5.45e-01 | 0.21 |
| 51668 | HSPB11 | GSM4909287 | Human | Breast | IDC | 1.18e-05 | 3.88e-01 | 0.2057 |
| 51668 | HSPB11 | GSM4909296 | Human | Breast | IDC | 7.34e-09 | -1.62e-02 | 0.1524 |
| 51668 | HSPB11 | GSM4909297 | Human | Breast | IDC | 4.81e-04 | -2.58e-02 | 0.1517 |
| 51668 | HSPB11 | GSM4909311 | Human | Breast | IDC | 6.01e-16 | -1.13e-01 | 0.1534 |
| 51668 | HSPB11 | GSM4909312 | Human | Breast | IDC | 5.21e-09 | 3.72e-02 | 0.1552 |
| 51668 | HSPB11 | GSM4909319 | Human | Breast | IDC | 1.87e-21 | -1.13e-01 | 0.1563 |
| 51668 | HSPB11 | GSM4909320 | Human | Breast | IDC | 2.40e-02 | 2.10e-02 | 0.1575 |
| 51668 | HSPB11 | GSM4909321 | Human | Breast | IDC | 2.87e-06 | -6.42e-02 | 0.1559 |
| 51668 | HSPB11 | NCCBC5 | Human | Breast | DCIS | 9.15e-05 | 6.08e-02 | 0.2046 |
| 51668 | HSPB11 | P1 | Human | Breast | IDC | 4.67e-07 | -1.35e-01 | 0.1527 |
| 51668 | HSPB11 | DCIS2 | Human | Breast | DCIS | 1.51e-52 | 1.10e-01 | 0.0085 |
| 51668 | HSPB11 | LZE4T | Human | Esophagus | ESCC | 8.80e-08 | 2.66e-01 | 0.0811 |
| 51668 | HSPB11 | LZE5T | Human | Esophagus | ESCC | 1.50e-03 | 6.89e-01 | 0.0514 |
| 51668 | HSPB11 | LZE7T | Human | Esophagus | ESCC | 2.32e-07 | 7.28e-01 | 0.0667 |
| 51668 | HSPB11 | LZE8T | Human | Esophagus | ESCC | 8.62e-10 | 3.70e-01 | 0.067 |
| 51668 | HSPB11 | LZE20T | Human | Esophagus | ESCC | 7.44e-07 | 4.79e-01 | 0.0662 |
| 51668 | HSPB11 | LZE22T | Human | Esophagus | ESCC | 6.60e-06 | 8.10e-01 | 0.068 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00303244 | Breast | IDC | lung development | 28/1434 | 177/18723 | 1.90e-04 | 3.15e-03 | 28 |
| GO:00303234 | Breast | IDC | respiratory tube development | 28/1434 | 181/18723 | 2.78e-04 | 4.26e-03 | 28 |
| GO:00605412 | Breast | IDC | respiratory system development | 30/1434 | 203/18723 | 3.85e-04 | 5.40e-03 | 30 |
| GO:00016555 | Breast | IDC | urogenital system development | 39/1434 | 338/18723 | 6.75e-03 | 4.68e-02 | 39 |
| GO:003032413 | Breast | DCIS | lung development | 27/1390 | 177/18723 | 2.73e-04 | 4.09e-03 | 27 |
| GO:003032313 | Breast | DCIS | respiratory tube development | 27/1390 | 181/18723 | 3.93e-04 | 5.41e-03 | 27 |
| GO:006054111 | Breast | DCIS | respiratory system development | 28/1390 | 203/18723 | 1.10e-03 | 1.19e-02 | 28 |
| GO:003070518 | Esophagus | ESCC | cytoskeleton-dependent intracellular transport | 133/8552 | 195/18723 | 1.48e-10 | 4.27e-09 | 133 |
| GO:001097013 | Esophagus | ESCC | transport along microtubule | 107/8552 | 155/18723 | 3.17e-09 | 6.80e-08 | 107 |
| GO:003150314 | Esophagus | ESCC | protein-containing complex localization | 139/8552 | 220/18723 | 1.14e-07 | 1.85e-06 | 139 |
| GO:00303239 | Esophagus | ESCC | respiratory tube development | 112/8552 | 181/18723 | 7.82e-06 | 7.69e-05 | 112 |
| GO:00605417 | Esophagus | ESCC | respiratory system development | 123/8552 | 203/18723 | 1.26e-05 | 1.15e-04 | 123 |
| GO:00303249 | Esophagus | ESCC | lung development | 109/8552 | 177/18723 | 1.40e-05 | 1.27e-04 | 109 |
| GO:00991114 | Esophagus | ESCC | microtubule-based transport | 115/8552 | 190/18723 | 2.54e-05 | 2.15e-04 | 115 |
| GO:00016559 | Esophagus | ESCC | urogenital system development | 177/8552 | 338/18723 | 7.51e-03 | 2.69e-02 | 177 |
| GO:00303242 | Liver | Cirrhotic | lung development | 65/4634 | 177/18723 | 2.49e-04 | 2.25e-03 | 65 |
| GO:00303232 | Liver | Cirrhotic | respiratory tube development | 66/4634 | 181/18723 | 2.82e-04 | 2.49e-03 | 66 |
| GO:003070511 | Liver | Cirrhotic | cytoskeleton-dependent intracellular transport | 68/4634 | 195/18723 | 9.54e-04 | 6.77e-03 | 68 |
| GO:0031503 | Liver | Cirrhotic | protein-containing complex localization | 75/4634 | 220/18723 | 1.13e-03 | 7.73e-03 | 75 |
| GO:00605411 | Liver | Cirrhotic | respiratory system development | 67/4634 | 203/18723 | 4.81e-03 | 2.52e-02 | 67 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HSPB11 | SNV | Missense_Mutation | rs751666876 | c.379N>T | p.Ala127Ser | p.A127S | Q9Y547 | protein_coding | deleterious(0.01) | benign(0.363) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
| HSPB11 | SNV | Missense_Mutation | c.332N>G | p.Ser111Cys | p.S111C | Q9Y547 | protein_coding | tolerated(0.05) | benign(0.251) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| HSPB11 | SNV | Missense_Mutation | c.31G>A | p.Glu11Lys | p.E11K | Q9Y547 | protein_coding | tolerated(0.34) | benign(0.29) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| HSPB11 | SNV | Missense_Mutation | c.338C>G | p.Thr113Ser | p.T113S | Q9Y547 | protein_coding | tolerated(0.17) | benign(0.116) | TCGA-CM-6674-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| HSPB11 | SNV | Missense_Mutation | novel | c.9N>C | p.Lys3Asn | p.K3N | Q9Y547 | protein_coding | tolerated_low_confidence(0.4) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HSPB11 | SNV | Missense_Mutation | rs769134105 | c.110C>T | p.Thr37Met | p.T37M | Q9Y547 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HSPB11 | SNV | Missense_Mutation | rs746875573 | c.394N>A | p.Val132Ile | p.V132I | Q9Y547 | protein_coding | tolerated(0.36) | benign(0.01) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| HSPB11 | SNV | Missense_Mutation | c.262N>C | p.Trp88Arg | p.W88R | Q9Y547 | protein_coding | tolerated(0.19) | benign(0.015) | TCGA-D1-A17R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| HSPB11 | SNV | Missense_Mutation | c.174N>T | p.Arg58Ser | p.R58S | Q9Y547 | protein_coding | tolerated(0.14) | benign(0.001) | TCGA-33-4566-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| HSPB11 | SNV | Missense_Mutation | novel | c.176T>A | p.Ile59Asn | p.I59N | Q9Y547 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-94-8490-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |